business
Monday, January 12, 2015
The Health Care Group Fresenius is a concern in the US go – and investors are excited: After US authorities have given the green light for the plant in Grand Iceland, the Group sales growth could significantly speed .
Charts
The share of the German health care group Fresenius SE was the star of the first half of the trading day on the German stock market. The paper listed in the DAX rose sharply and is at noon with an increase of 3.7 percent at 45.16 euros. In the past six months the stock has risen already tidy and had increased by 17.4 percent. The French bank Societe Generale has also left the classification of Fresenius SE to “buy” with a price target of EUR 50.10
The reason:. Fresenius is a concern in the US go. The Company may in the future again produce in its US plant in Grand Iceland, the 2012 has been criticized by the US authorities, new generic drugs. Reason is a better classification of the work by the US Food and Drug Administration after an inspection in October 2014 the company said.
“Significant impact on share price dispelled”
Read more about
The decision could now be resolved a “production Jam” and bottleneck in the production of new products in the pipeline, the daughter Kabi said one dealer. Analysts at Morgan Stanley noted already before the higher classification by the FDA, such a move would a significant impact on the share price dispelled. Because that’ll organic sales growth accelerated considerably.
Fresenius received in February 2012 a blue letter from the FDA because the agency had found, inter alia errors in the documentation of the production process at the plant in the US state of New York , Fresenius was allowed despite these shortcomings continue to produce approved drugs, but did not apply for new registrations. This lock is now canceled.
Source: n-tv.de
No comments:
Post a Comment